Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
Madrigal may gain the first NASH approval in early 2024; numerous candidates are lining up behind.
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
